scholarly journals Clinical Evaluation of Efficacy and Safety of Combined Topical Timolol and Oral Propranolol in Children with Infantile Hemangioma

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Abdulameer Abdulbari Abdulhameed ◽  
Kalil Esmail Al-Hamdi ◽  
Muntaha Abdulhadi Mathkoor
Keyword(s):  
Clinical Evaluation ◽  
Infantile Hemangioma ◽  
Efficacy And Safety ◽  
Oral Propranolol

scholarly journals Efficacy and safety of oral propranolol for infantile hemangioma in Japan

2017 ◽  
Vol 59 (8) ◽  
pp. 869-877 ◽  
Author(s):  
Tsuyoshi Kaneko ◽  
Satoru Sasaki ◽  
Naoko Baba ◽  
Katsuyoshi Koh ◽  
Kiyoshi Matsui ◽  
...  
Keyword(s):  
Infantile Hemangioma ◽  
Efficacy And Safety ◽  
Oral Propranolol

scholarly journals The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: A case series

2021 ◽  
pp. 106120
Author(s):  
Prasetyanugraheni Kreshanti ◽  
Nandya Titania Putri ◽  
Valencia Jane Martin ◽  
Chaula Luthfia Sukasah
Keyword(s):  
Head And Neck ◽  
Case Series ◽  
Neck Region ◽  
Infantile Hemangioma ◽  
Head And Neck Region ◽  
Oral Propranolol

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial

2017 ◽  
Vol 35 (10) ◽  
pp. 1041-1048 ◽  
Author(s):  
Ian Smith ◽  
Denise Yardley ◽  
Howard A. Burris ◽  
Richard De Boer ◽  
Dino Amadori ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Adverse Events ◽  
Early Breast Cancer ◽  
Clinical Evaluation ◽  
Hormone Receptor ◽  
Hazard Ratio ◽  
Efficacy And Safety ◽  
Node Positive ◽  
To Receive

Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) –positive and node-positive early breast cancer (eBC). Methods Postmenopausal women with HR-positive and node-positive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or until recurrence of disease. Patients were stratified on the basis of the number of lymph nodes and human epidermal growth factor receptor 2 status. The primary end point was 5-year disease-free survival (DFS), and the key secondary end points were overall survival and safety. Results A total of 4,136 patients were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075). The final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]). The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio, 0.93; 95% CI, 0.80 to 1.07; P = .3150). Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups. The 5-year estimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio, 0.98; 95% CI, 0.82 to 1.17; P = .7916). Most common grade 3 to 4 adverse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adverse events), hypertension (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%). Conclusion Letrozole did not demonstrate significantly superior efficacy or safety compared with anastrozole in postmenopausal patients with HR-positive, node-positive eBC.

Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair

2006 ◽  
Vol 46 (1) ◽  
pp. 94-98 ◽  
Author(s):  
John E. Wolf ◽  
Douglas Shander ◽  
Ferdinand Huber ◽  
Joseph Jackson ◽  
Chen-Sheng Lin ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Facial Hair
Sign in / Sign up

Export Citation Format

Share Document